Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Regulation of Urinary Bladder Carcinogenesis and Progression by SPARC

Funder: National Cancer Institute

Funding period
USD 1.7 M
Funding amount
Abstract
? DESCRIPTION (provided by applicant): Bladder cancer (BCa) is the fourth malignancy affecting the genitourinary system in United States. With estimated, 73,510 new cases and 14,880 deaths from BCa in 2014 in The United States. Almost 25-40% of patients present with muscle invasive disease, and approximately 50% will harbor distant metastases. Even after radical eradication of the primary tumor, recurrence is common and survival rates are less than 60%. Prognostic and therapeutic approaches are hampered by presentation with an already established disease, lack of appropriate normal controls and predictive/prognostic biomarkers with no approved new drugs in the past 30 years. Secreted Protein Acidic and Rich in Cysteine (SPARC) is a matricellular glycoprotein that exhibits contextual expression and functions maintaining tissue homeostasis. SPARC is expressed and secreted by malignant and/or tumor-associated stromal cells and transduces intra and extracellular signals, orchestrating tumor progression. The role of SPARC in different cancers is unfolding and its role in BCa is still elusive. The overall goal of this proposal is to investigate the expression and disease association of SPARC in BCa. My preliminary data show that SPARC expression in BCa cell lines was negatively associated with their in vitro proliferation and in vivo tumorigenicity. Chemical-carcinogenesis model of BCa, in SPARC knockout and wild-type mice showed that urothelial carcinogenesis and progression were significantly accelerated in KO mice. Inflammation is the forerunner of the disease and was accompanied by accelerated preneoplasia and overt neoplasia. The overall hypothesis is that SPARC exhibits differential expression and functions in BCa microenvironment. Our specific aims are: (i) Characterize the interactions between cancer cells and macrophages and their regulation by SPARC. The hypothesis for Aim#1 is that SPARC plays an important anti-inflammatory role regulating cancer cell-macrophage crosstalk. (ii) Define the molecular basis for SPARC-mediated cell cycle arrest of bladder cancer cells. The hypothesis for Aim#2 is that SPARC restrain cancer cell proliferation through cell cycle arrest through autocrine and paracrine effects involving cell surface receptor(s). (iii) Evaluate the functional and predictive relevance of SPARC in human and murine BCa. The hypothesis for Aim#3 is that SPARC is differentially expressed in cancerous versus non-cancerous cells as a function of grade and stage. Our proposal includes cell, molecular, chemoproteomic, genetic models and human tumor tissues aimed at understanding the regulation, function and disease aspects of SPARC in BCa. Fundamental findings that we hope to show include a function for SPARC regulating the rate limiting steps in BCa pathobiology, namely inflammation and cell cycle regulation.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting TAM (Tyro3-Axl-Mer) family of transmembrane receptor tyrosine kinases in bladder cancer.

Bladder Cancer Advocacy Network to Arpita Roy

USD 1,700
2018 - 2018
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 902,622
2018 - 2023
Project list item
Subtyping Bladder Cancer: A Multi-omic, Exposure-informed, Genealogical Approach (MErGE)

National Cancer Institute to HEIDI ANNE HANSON

USD 298,810
2018 - 2023
Project list item
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Canadian Institutes of Health Research to Murray Dale Krahn, Girish Satish Kulkarni, William Wai Lun Wong, George Andrew Tomlinson, Nathan Perlis, Wassim Kassouf, Peter Colin Black, Shabbir Muhammad Husayn Alibhai

USD 77,161
2018 - 2019

System

Categories
  • FOR (ANZSRC)

    0601 Biochemistry and Cell Biology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science